Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Tumor Immunotherapy01:27

Tumor Immunotherapy

524
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
524
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

164
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
164
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Targeted cancer therapy: the initial high concentration may slow down the selection for resistance.

Aging·2024
Same author

My battle with cancer. Part 1.

Oncoscience·2024
Same author

Towards disease-oriented dosing of rapamycin for longevity: does aging exist or only age-related diseases?

Aging·2023
Same author

Evaluation of off-label rapamycin use to promote healthspan in 333 adults.

GeroScience·2023
Same author

Apoptotic cell death in disease-Current understanding of the NCCD 2023.

Cell death and differentiation·2023
Same author

Cancer prevention with rapamycin.

Oncotarget·2023

相关实验视频

Updated: Jun 30, 2025

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.0K

从奥西默提尼布到预防性组合.

Mikhail V Blagosklonny1

  • 1Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.

Oncotarget
|March 18, 2024
PubMed
概括
此摘要是机器生成的。

第一线 osimertinib 改善了EGFR突变肺癌的中位数无进展生存期 (PFS),但可能会伤害一些患者. 预防性组合疗法为大多数患者提供了一种潜在的解决方案,可以增加PFS,而不会造成伤害.

关键词:
欧洲农业基金会 (EGFR) 是一个.在NSCLCLC中,我们可以看到NSCLCLC.亚法提尼布 (Afatinib) 是一种卡普马提尼布 (capmatinib) 是一种药物.盖菲提尼布 (gefitinib) 是一种药物.肺癌是一种肺癌.电阻的阻力可以

更多相关视频

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

2.8K
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.0K

相关实验视频

Last Updated: Jun 30, 2025

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.0K
A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

2.8K
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.0K

科学领域:

  • 在瘤学瘤学.
  • 药理学 药理学是指药理学的学科.
  • 遗传学 是一个遗传学.

背景情况:

  • 表皮生长因子受体 (EGFR) 突变驱动肺癌.
  • 奥西默提尼布是EGFR突变肺癌的第一线治疗方法,延长了中位数无进展生存期 (PFS).
  • 然而,与早期治疗相比,一小部分患者经历了奥西默蒂尼布的PFS降低.

研究的目的:

  • 评估EGFR突变肺癌患者的一个子集的第一线 osimertinib 的潜在危害.
  • 建议先发制人组合疗法 (PC) 来改善PFS并避免伤害.
  • 为了探索MET驱动的肺癌的PC.

主要方法:

  • 对 osimertinib 的 PFS 数据与第一代 TKIs 的比较分析.
  • 预防性组合疗法的概念化.
  • 探索MET驱动的肺癌的治疗策略.

主要成果:

  • 第一线 osimertinib 延长了 PFS 的中位数,但在15-20% 的患者中降低了个体 PFS.
  • 奥西默蒂尼布,阿法提尼布/盖菲提尼布和卡普马提尼布的综合性PC可以显著增加80%的患者的PFS.
  • 拟议的PC旨在最大限度地提高PFS的好处,而不会造成伤害.

结论:

  • 由于整体中位数的PFS增长,奥西默提尼布对于一线治疗至关重要,尽管潜在的个人伤害.
  • 预防性组合疗法是一种有前途的策略,可以提高EGFR突变和MET驱动的肺癌的治疗效率和患者的治疗结果.
  • 对全面的预防性组合进行进一步的研究是有必要的.